Discover Biotech Webinar Pharma FDA & EMA ONCOLife Contact

Clinical Trials

Perioperative Durvalumab Regimen Improves EFS and OS in Muscle-Invasive Bladder Cancer

FDA & EMA

FDA Grants Fast Track Designation to RPTR-1-201 for Advanced Triple- Breast Cancer

ONCOLife

PHERGain Data Support Chemo-Free Treatment With 90% Five-Year RFS in Breast Cancer

ONCOLife

Targeting RNase H2 Exposes a New Therapeutic Vulnerability in Triple-Negative Breast Cancer

ONCOLife

ALK Mutation Emerges as a Potential Biomarker for Pan-Cancer Immunotherapy Benefit

Clinical Trials

Misinformation Drives Over 16 Million Americans Toward High Skin Cancer Risk

ONCOLife

Real-World Analysis Links Community Oncology Care to Longer Survival in Multi-Cancer

ONCOLife Issues

Featured Articles

FDA Approves First All-Oral INQOVI Plus Venetoclax Regimen for Newly Diagnosed AML

14 May 2026

The FDA has approved INQOVI (decitabine and cedazuridine) plus venetoclax for newly diagnosed AML in adults aged 75 years or older, or those ineligible for intensive induction chemotherapy. In the Phase 2 ASCERTAIN-V study, 41.6% of patients achieved complete ...

Trending Articles

Ozekibart Shows Encouraging Late-Line Activity in Metastatic Colorectal Cancer

FDA Grants Breakthrough Status to First Viral Liquid Biopsy in Hepatocellular Carcinoma

FDA & EMA

21 April 2026

FDA Gives Priority Review to PADCEV Plus Pembrolizumab in MI Bladder Cancer

FDA & EMA

20 April 2026

AACR26 Data Show Multi-Biomarker MCED Approach Improves Early Cancer Detection

ONCOLife

17 April 2026

FDA Grants Breakthrough Status to First Urine-Based Multi-Cancer Early Detection Test

ONCOLife

16 April 2026

Daraxonrasib Doubles Overall Survival in Previously Treated Metastatic Pancreatic Cancer

AI Nodule Detection Helps Sarasota Memorial Reach 75% Early Lung Cancer Diagnosis

AI

15 April 2026

Illumina Launch 100 K Genome Effort to Advance Cancer and Rare Disease Research

AI

15 April 2026

Zenocutuzumab Gains NCCN Support as FDA Review Advances in Cholangiocarcinoma

FDA & EMA

15 April 2026

Phase 2 Data Position Trastuzumab Pamirtecan as a Promising Option in Endometrial Cancer

ONCOLife

13 April 2026

Mocertatug Rezetecan Shows Strong Responses in Ovarian and Endometrial Cancers

FDA Grants Priority Review to Ifinatamab Deruxtecan in Pretreated ES-SC Lung Cancer

FDA & EMA

13 April 2026

MD Anderson Study Identifies DPY30 as Therapeutic Target in Pancreatic Cancer

ONCOLife

11 April 2026

Blocking DHODH Helps Triple Combination Overcome Resistance in Lung Cancer

ONCOLife

10 April 2026

New Strategy Blocks NMD, Unmasks Hidden Tumor Antigens, and Boosts Immunotherapy

ONCOLife

10 April 2026